Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use

Abstract Human immunodeficiency virus (HIV) patients have more aggressive presentation of colorectal cancer (CRC) and less favourable outcome. Bevacizumab is an antiangiogenic agent that has emerged as a major drug for metastatic CRC. However, few data are available on the safety of bevacizumab in HIV patients. In the light of a case study, we briefly draw intention on how angiogenesis inhibitors could interact with antiviral tri-therapy.

[1]  S. Steinberg,et al.  Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  É. Oksenhendler,et al.  The spectrum of malignancies in HIV‐infected patients in 2006 in France: The ONCOVIH study , 2011, International journal of cancer.

[3]  J. Gottdiener,et al.  High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. , 2011, Clinical Infectious Diseases.

[4]  Cyrus Chargari,et al.  Inhibitors of Angiogenesis: New Hopes for Oncologists, New Challenges for Anesthesiologists , 2010, Anesthesiology.

[5]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[6]  É. Oksenhendler,et al.  AIDS-related malignancies: state of the art and therapeutic challenges. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  U. Tirelli,et al.  Bevacizumab plus Irinotecan-, Fluorouracil-, and Leucovorin-Based Chemotherapy with Concomitant HAART in an HIV-Positive Patient with Metastatic Colorectal Cancer , 2008, Oncology Research and Treatment.

[8]  L. Lekakis,et al.  First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: a case report. , 2008, European Journal of Gastroenterology and Hepathology.

[9]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[10]  R. Beart,et al.  Colorectal cancer in HIV-infected patients: a case control study , 2007, International Journal of Colorectal Disease.

[11]  O. Mir,et al.  Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? , 2007, Journal of the National Cancer Institute.

[12]  Kholoud Porter,et al.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.

[13]  I. Zachary,et al.  Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. , 2001, Cardiovascular research.

[14]  V. Weinberg,et al.  The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. , 1999, International journal of radiation oncology, biology, physics.

[15]  J. V. Von Roenn,et al.  Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. , 1997, The New England journal of medicine.